gsk201201106kamend.htm
FORM 6-K/A
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending January 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 

 



 
 
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
 
I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
 
 
On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2011:
 
 
GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award- Annual Dividend Reinvestment
 
Non-Executive Director
No. of Ordinary Shares
Average Price (£)
No. of ADSs
Average Price ($)
Sir Christopher Gent
3,072.732
14.70
   
Prof Sir Roy Anderson
408.069
14.70
   
Dr Stephanie Burns
   
361.105
45.53
Ms Stacey Cartwright
3.865
14.70
   
Mr Lawrence Culp
   
1,133.685
45.53
Sir Crispin Davis
2,536.065
14.70
   
Ms Judy Lewent
   
1.998*
45.53
Sir Deryck Maughan
   
1,033.536
45.53
Mr James Murdoch
474.157
14.70
   
Dr Daniel Podolsky
   
623.023
45.53
Mr Tom de Swaan
612.754
14.70
   
Sir Robert Wilson
710.997
14.70
   
 
The Company and the Non-Executive Directors were informed of these allocations on
 
 
3 January 2012.
 
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
 
 
Company Secretary
 
 
10 January 2012
 


 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: January 10, 2012
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc